Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
T2DM, as one of the most common chronic metabolic diseases, is also one of the most significant risk factors for CVD and CKD. GLP-1RA, SGLT2i, and nsMRAs have emerged as novel therapeutic agents to comprehensively manage T2DM-related CVD and CKD. We conducted a network meta-analysis to compare the efficacy and safety of GLP-1RAs, SGLT2i, and nsMRA in patients with T2DM.
Authors
- Xuedong An (ORCID: https://orcid.org/0000-0002-2787-1645)
- Yuehong Zhang (ORCID: https://orcid.org/0000-0002-1990-9439)
- Xueqin Li (ORCID: https://orcid.org/0000-0001-5270-4825)
- Guangjian Yang (ORCID: https://orcid.org/0000-0002-7611-2370)
- He Zhang
- Qian-You Jia
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Xiyuan Hospital (CN)
Publication Details
- Journal
- World Journal of Diabetes
- Published
- 2025-11-14
- DOI
- https://doi.org/10.4239/wjd.v16.i11.111280
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29